1. Introduction
===============

Cervical cancer is a considerable health crisis for women; it is the fourth most common cancer worldwide and the fourth leading cause of cancer death.^\[[@R1],[@R2]\]^ Surgery, radiation, and chemotherapy were recommended as standard treatment approaches by the National Comprehensive Cancer Network (NCCN) and the International Federation of Gynecology and Obstetrics (FIGO) according to the disease stage at the time of diagnosis. For patients with FIGO stage Ia1 to IIa1 cervical cancer, surgery including radical hysterectomy and pelvic lymph node dissection was the preferred therapy method.^\[[@R3]\]^ However, for disease of FIGO stage IIb and above, namely advanced stage cervical cancer, hysterectomy is not usually performed based on the newest guidelines.^\[[@R4]\]^

In some countries and clinical studies, selected cases of local advanced cervical cancer (LACC, stages Ib2, IIa2, and IIb) have been treated with neoadjuvant chemotherapy (NACT) following radical surgery.^\[[@R5]--[@R7]\]^ Data from clinical studies suggested that NACT followed by surgery did not improve survival compared with surgery alone for LACC.^\[[@R8]\]^ A previous meta-analysis conducted by a collaboration group that included 9 trials also indicated that NACT can result in downstaging, by not only decreasing tumor size, but also by controlling lymph node metastasis. However, NACT failed to improve the survival of patients with LACC.^\[[@R5]\]^ These clinical data meant that the guidelines do not recommend the use of NACT for LACC.

Previous studies found that the NACT treatment response has been adopted as an explicit predictive marker for the long-term prognosis of several cancers, such as breast cancer.^\[[@R9],[@R10]\]^ Other studies also implied that achievement of a therapy response was an independent prognostic parameter for LACC treated with NACT. A study conducted by Buda et al retrospectively analyzed 446 patients with stages Ib2--IVa disease who were treated with NACT followed by radical surgery. Results suggested that patients with an optimal pathologic response had better overall survival (OS) (hazard ratio (HR) = 4.65, 95% confidence interval (95% CI): 2.75--7.85, *P* \< .0001), implying that the NACT response is a predictive marker for long-term survival.^\[[@R11]\]^ Another study from China of 853 patients with LACC (stage Ib2--IIb) who received NACT suggested that a clinical response was a predictive marker of a favorable prognosis (HR = 1.83, 95% CI: 1.18--2.85, *P *= .007).^\[[@R12]\]^ However, the data and conclusions regarding the predictive value of the NACT response all came from sporadic and small studies. This was the case for both pathologic and clinical responses.

Thus, the purpose of this meta-analysis was to analyze the published data of NACT for LACC to determine the tumor treatment response, including the pathologic and clinical response. We aimed to determine whether this could predict long-term outcomes in LACC.

2. Materials and methods
========================

2.1. Literature search
----------------------

Eligible articles for this comprehensive meta-analysis were identified using the electronic databases of PubMed and Web of Science up to July 2017. Search terms including "cervical cancer;" "neoadjuvant chemotherapy or preoperative chemotherapy;" and "prognosis or survival" were researched in the title, abstract, or keywords of published articles. The references of the eligible publications were intensively reviewed to identify additional possible articles for inclusion.

2.2. Eligibility criteria
-------------------------

The eligible studies in this analysis were also required to meet all of the following criteria: NACT had to be administered for cervical cancer and followed by radical surgery; detailed survival data had to be reported for clinical or pathologic responders; the full text of original studies had to be written in English; and published articles must containing sufficient data to calculate the HR and 95% CI.

2.3. Qualitative assessment and data extraction
-----------------------------------------------

The quality of the included studies was evaluated by 2 investigators based on the Newcastle--Ottawa Scale (NOS).^\[[@R13]\]^ Further, 2 other authors independently evaluated and extracted the data in a standardized manner. Any disagreements were resolved by discussion with another investigator. The following relevant data from each included article were extracted: first author, study country, publication year, total number of included patients, duration of follow-up, primary FIGO stage, percentages of patients achieving clinical and pathologic responses, NACT regimen, and survival data.

In order to avoid bias, the NACT clinical response was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.^\[[@R14]\]^ The clinical responses were classified as complete resolution (CR) and a partial response (PR). Meanwhile, the pathological response was determined by pathological analysis post-NACT and surgery. Pathological responders were defined as a pathological CR (pCR) and a PR, and a pathological PR was defined as cervical cancer residual disease with less than 3 mm stromal invasion.

2.4. Statistical analysis
-------------------------

The HR and 95% CI were utilized to assess the association between patients with LACC who achieved a clinical and pathologic response from NACT and long-term survival (OS and disease-free survival, DFS). A fixed effect model (Mantel--Haenszel method) was used when there was minimal heterogeneity among the eligible studies. When significant heterogeneity existed, the random effect model (DerSimonian--Laird method) was used. The *I*^2^ test was applied for the interstudy heterogeneity of the HRs. Potential publication bias was evaluated using the funnel plot with Begg and Egger tests. Review Manager (version 5.3, Cochrane Collaboration, Oxford) and Stata (version 12; Stata Corporation, College Station, TX) were used for statistical analyses.

3. Results
==========

3.1. Characteristics of eligible studies
----------------------------------------

A total of 759 related publications were identified from the PubMed and Web of Science databases and their bibliographies of relevant articles. After titles and abstracts were reviewed, the full texts of the remaining 39 potential studies were reviewed. Twenty-six articles were excluded because they did not meet the selection criteria. Ultimately, 13 studies were included for the final meta-analysis^\[[@R11],[@R12],[@R15]--[@R25]\]^ (Fig. [1](#F1){ref-type="fig"}).
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The baseline main traits of all included studies are listed in Table [1](#T1){ref-type="table"}. In total, 4727 cases were included from 13 publications that provided the clinical and pathological response data from NACT. The number of patients in the eligible studies varied from 52 to 853. Most of the articles involved patients with FIGO stage Ib and IIb cervical cancer. According to the original studies, the pathological response rate after NACT was 7.5% to 78.81%, and the clinical response rate was 58.49% to 86.54%. The most used NACT regimen consisted of platinum and/or taxane-based chemotherapy.

###### 

Characteristics of the eligible studies.
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3.2. Treatment response and cervical cancer OS
----------------------------------------------

Published data of the relationship between pathologic response and OS were acquired from 2 of the 13 eligible studies and included 519 patients. The combined analysis showed that NACT pathologic responders could achieve favorable OS (pooled HR = 5.45, 95% CI = 3.42--8.70; *P* \< .00001). A heterogeneity test was performed, and did not detect heterogeneity (*I*^2^ = 4%, *P* = .31). A fixed effect model was adopted (Fig. [2](#F2){ref-type="fig"}).
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One thousand two-hundred fifty-five patients from 7 included studies provided the association between a clinical response and the OS data. Heterogeneity testing revealed *I*^2^ = 3%, showing that no heterogeneity existed (*P* = .41). In the fixed effects model, the summary HR was 3.36 (95% CI, 2.41--4.69; *P* \< .00001) (Fig. [2](#F2){ref-type="fig"}).

3.3. Treatment response and cervical cancer DFS
-----------------------------------------------

Three studies including 1607 patients provided the association between pathologic response from NACT and DFS. Heterogeneity testing revealed *I*^2^ = 0% and *P* for heterogeneity .63. The HR was 3.61 (95% CI = 2.0--6.52; *P* \< .00001), which showed that a better pathologic response was associated with favorable DFS (Fig. [3](#F3){ref-type="fig"}).
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Eight eligible publications showed the association between the clinical response and DFS data. Finally, 2443 patients were included in the pooled analysis. NACT responders showed an association with favorable DFS (pooled HR = 2.36, 95% CI = 1.82--3.06, *P* \< .00001), and the results did not show heterogeneity (*I*^2^ = 45%, *P* = .08) (Fig. [3](#F3){ref-type="fig"}).

3.4. Sensitivity analysis and publication bias
----------------------------------------------

Sensitivity analyses were conducted to estimate heterogeneity in this meta-analysis, and the analysis results showed no potential heterogeneity (data not shown). Publication bias was estimated by visual symmetry of funnel plots and the Egger test; the symmetric funnel plots indicated that no significant publication bias existed in this study (Fig. [4](#F4){ref-type="fig"}).
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4. Discussion
=============

Nowadays, the canonical therapy for cervical cancer is performed according to the 2009 FIGO staging system. Surgery or radiotherapy (RT) are optimized therapy methods for early stage cervical cancer.^\[[@R4]\]^ In contrast, the appropriate therapy for LACC (stages Ib2, IIa2, and Ib) remains uncertain.^\[[@R26]\]^ Major therapy options include radical surgery with or without postoperative RT; NACT as an alternative treatment method for LACC has also been applied for several years.^\[[@R27]\]^ NACT helps to downstage tumors, increase their resectability, and potentially make young patients eligible for fertility-sparing surgery.^\[[@R28]\]^ Despite the benefits, NACT could also conceal the primary pathologic features of the disease, such as vascular invasion and the number of involved lymph nodes.^\[[@R12],[@R29]\]^ A previous randomized controlled trial carried out by the Japan Clinical Oncology Group indicated that patients with stage Ib2, IIa2, or IIb cervical cancer who receive NACT before radical surgery are less likely to require postsurgery radiation therapy; however, it did not improve OS.^\[[@R30]\]^ To date, the lack of large-scale randomized controlled studies and evidence-based medical evidence to support NACT means that NACT is not recommended in the NCCN guidelines for patients with LACC.

The NACT treatment response has been adopted as an explicit surrogate predictive marker of prognosis in many cancers, such as local advanced breast cancer (LABC). In contrast, for LACC, the prognosis predictive value of the NACT response has not been fully investigated. In this study, a pooled analysis about the prognostic predictive role of the NACT response in LACC (including the pathological and clinical response) was performed using 13 previously published studies containing 4727 cases. The treatment clinical response and the pathological response rates ranged from 58.49% to 86.54% and 7.5% to 78.81%, respectively; the treatment response indicated that LACC was sensitive to chemotherapy.

The treatment decisions for cervical cancer postsurgery were mostly dependent on postoperative pathological examination; however, for LACC post-NACT followed by radical surgery, it was hard to identify an alternative therapy according to the post-NACT pathological diagnosis. Therefore, it was necessary to identify prognostic indicators from NACT. Our combined results suggested that a clinical response to NACT was favorable for OS and DFS. Further, the pathological response to NACT predicts favorable OS and DFS. Hence, the NACT response could be a marker to predict survival and a marker for postsurgery treatment could be tailored to individual patients (Fig. [5](#F5){ref-type="fig"}).
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This study was properly designed using statistical analysis based on previous published studies, and no heterogeneity was observed when pooling the data. However, there were still some limitations. First, the majority of the included articles were retrospective. Second, 9 out of 13 studies were performed in China, which may have resulted in selection bias. Finally, great differences existed among the included studies. The chemotherapy regimens might be the main reason for response diversity; in NACT for LACC, a platinum-based regimen was used widely. Chemotherapeutic drugs, like irinotecan, docetaxel, nedaplatin, bleomycin, vincristine, and 5-fluorouracil (5-FU) were also used.

In conclusion, this meta-analysis demonstrated that the responsiveness to NACT, including the clinical and pathological response, was associated with a favorable prognosis for patients with LACC. Furthermore, better designed studies are required to clarify the prognostic predictive value of the NACT response in patients with LACC. This will also allow us to establish selective criteria for patients who would obtain the greatest survival benefit from NACT.

Acknowledgment
==============

We wanted to acknowledge members of our research group for helpful insights.

Author contributions
====================

Data curation: Yunshan Zhu, Xiao Zhang.

Writing---original draft: Yunshan Zhu.

Methodology: Jianhua Yang.

Writing---review and editing: Jianhua Yang, Songying Zhang.

Formal analysis: Danxia Chen.

Project administration: Songying Zhang.

Abbreviations: FU = 5-fluorouracil, 95% CI = 95% confidence intervals, CR = complete resolution, DFS = disease-free survival, FIGO = International Federation of Gynecology and Obstetrics, HR = hazard ratios, LACC = local advanced cervical cancer, NACT = neoadjuvant chemotherapy, NCCN = National Comprehensive Cancer Network, NOS = Newcastle--Ottawa Scale, OS = overall survival, pCR = pathological complete resolution, PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumors, RT = radiotherapy.

Funding: This work was supported by the Key Research and Development Program of Zhejiang Province (2017C03022).

Ethical approval and patient consent: This study does not require ethical approval and patient consent because the study was a systematic review of previous studies and does not involve patients.

The authors have no conflicts of interest to disclose.
